Hester Biosciences Limited announced the outcome of its Board Meeting held on 30 January 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter and nine months period ended 31 December 2025. Concurrently, the Board approved the re-appointment of Mr. Rajiv Gandhi as CEO & Managing Director for a period of three years, effective from 1 April 2026, subject to shareholder approval via postal ballot. In terms of financial performance, on a standalone basis, Q3 FY26 saw a 12% increase in revenue from operations to ₹703.54 million and a significant 140% rise in Profit After Tax (PAT) to ₹106.69 million. The Poultry Healthcare Division demonstrated strong growth with a 32% increase in Q3 FY26 revenue. However, the Animal Healthcare Division experienced a 38% decline in Q3 FY26 revenue, primarily due to delays in government-led immunisation programs. For the nine-month period ended 31 December 2025 (9M FY26), standalone revenue from operations decreased by 5% to ₹1,984.23 million, while PAT increased by 16% to ₹257.16 million. On a consolidated basis, Q3 FY26 revenue from operations grew by 22% to ₹774.15 million, but PAT declined by 18% to ₹93.10 million. For 9M FY26, consolidated revenue from operations increased by 1% to ₹2,324.89 million, with PAT rising by 50% to ₹409.37 million. The company has also capitalized its fill-finish facility, doubling its drug product capacity. The company highlighted that the execution of PPR orders under the national immunisation program will commence in February 2026. Hester Biosciences aims to build a more balanced business by reducing dependence on tender-based revenues and deepening its presence in commercial and private markets.
